menu search

CCCC / C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial

C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial
C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL).  The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting. Read More
Posted: Apr 8 2022, 14:19
Author Name: Benzinga
Views: 110856

CCCC News  

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

By Zacks Investment Research
May 4, 2023

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares t more_horizontal

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

By Zacks Investment Research
February 23, 2023

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -5.56% and 66.66%, respectively, for the quarter ended December 2022. Do the more_horizontal

Why C4 Therapeutics Stock Is Plunging Today

By Benzinga
April 8, 2022

Why C4 Therapeutics Stock Is Plunging Today

C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongo more_horizontal

C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial

By Benzinga
April 8, 2022

C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial

C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgk more_horizontal


Search within

Pages Search Results: